Another stem cell patent -- US 7,282,222
A PRNewswire release noted:
Using this now-patented technology, exclusively licensed to CellCyte from the US Department of Veterans Affairs, the company is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased and other target organs, such as the heart. (...)The company's first product in development, CCG-TH30, is designed to target autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack."
Refer to US 7,282,222.
The release also notes:
CellCyte Genetics Corp. is completing preclinical studies and in 2008 will then move to a Phase I human clinical trial using the compound for the heart.
In addition to this indication, the patenting of the technology opens up the possibility for gene therapy and the delivery of a variety of other payloads to the heart via the stem cell vehicle.
Using this now-patented technology, exclusively licensed to CellCyte from the US Department of Veterans Affairs, the company is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased and other target organs, such as the heart. (...)The company's first product in development, CCG-TH30, is designed to target autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack."
Refer to US 7,282,222.
The release also notes:
CellCyte Genetics Corp. is completing preclinical studies and in 2008 will then move to a Phase I human clinical trial using the compound for the heart.
In addition to this indication, the patenting of the technology opens up the possibility for gene therapy and the delivery of a variety of other payloads to the heart via the stem cell vehicle.
posted by Lawrence B. Ebert at 10:10 AM
0 Comments:
Post a Comment
<< Home